Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers after Oral Doses of Saxagliptin
Study identifier:D1680C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open label, Pharmacokinetic Study of Single and Multiple Doses of 5 mg Saxagliptin in Healthy Chinese Subjects Living in China
Medical condition
Type 2 Diabetes
Phase
Phase 1
Healthy volunteers
Yes
Study drug
Saxagliptin
Sex
All
Actual Enrollment
34
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Oct 2008
Primary Completion Date: 01 Oct 2008
Study Completion Date: 01 Oct 2008
Study design
Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Bristol-Myers Squibb
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Peter Öhman
AstraZeneca
